Literature DB >> 35976387

[Perioperative management of coagulation in otorhinolaryngologic surgery].

F Stahl1, H Rühl2, G Goldmann2, S Strieth2, T Send2.   

Abstract

Considering the increasing number of patients suffering from drug-induced coagulation disorders caused by antiplatelet or anticoagulant therapy, the right balance between minimizing the risk of bleeding and the risk of a venous thrombosis or embolism during otorhinolaryngologic (ORL) surgery is becoming increasingly important. According to a recent study, the highest risk of intraoperative bleeding in ORL surgery is associated with transoral tumor surgery, tonsillectomy, thyroidectomy, and glomus tumor surgery. The risk of venous thrombosis or embolism during ORL surgery is estimated to be 1%, and increases to 6% among tumor patients. Currently, there is no general recommendation for perioperative hemostatic management because of the limited available data. In the majority of patients who continue antiplatelet therapy with acetylsalicylic acid (ASS) to prevent thromboembolic events, the perioperative bleeding risk is considered to be acceptable. For patients with dual antiplatelet therapy, surgical procedures should be only performed after adaption of the medication.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Anticoagulants; Bleeding; Blood coagulation; Hemostasis; Tonsillectomy

Mesh:

Substances:

Year:  2022        PMID: 35976387     DOI: 10.1007/s00106-022-01201-w

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.330


  2 in total

1.  Etiology, Management, and Outcome of Pediatric Epistaxis.

Authors:  Thorsten Send; Mattis Bertlich; Klaus Wolfgang Eichhorn; Rainer Ganschow; Darius Schafigh; Fritz Horlbeck; Friedrich Bootz; Mark Jakob
Journal:  Pediatr Emerg Care       Date:  2019-01-07       Impact factor: 1.454

2.  Management and outcome of epistaxis under direct oral anticoagulants: a comparison with warfarin.

Authors:  Thorsten Send; Mattis Bertlich; Fritz Horlbeck; Darius Schafigh; Saskia Freytag; Klaus W Eichhorn; Ingo Gräff; Friedrich Bootz; Mark Jakob
Journal:  Int Forum Allergy Rhinol       Date:  2018-10-03       Impact factor: 3.858

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.